FOSTER CITY, CALIFORNIA, March 24, 2026
Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a deal valued at approximately $1.675 billion upfront with up to $500 million in milestone payments, strengthening its position in autoimmune and inflammatory disease therapeutics. The acquisition brings OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T cell engager, into Gilead’s growing inflammation portfolio, highlighting the company’s strategic focus on next-generation immune-modulating therapies.
Strategic Acquisition Expands Autoimmune Innovation Pipeline
The acquisition of Ouro Medicines represents a major step in Gilead’s strategy to advance first-in-class therapies targeting immune-mediated diseases. At the center of this deal is OM336, a novel bispecific antibody designed to redirect T cells to eliminate pathogenic B cells and plasma cells, offering a potentially transformative approach to treating severe autoimmune conditions.
OM336 has already shown promising early clinical results in Phase 1/2 studies, demonstrating strong efficacy and a differentiated safety profile following a single treatment cycle. The therapy is being evaluated in rare and serious diseases such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), both of which have significant unmet medical needs.
Importantly, OM336 has received both Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration, reinforcing its potential to address critical gaps in current treatment options. The therapy is expected to enter registrational studies by 2027, positioning it as a key future asset within Gilead’s pipeline.
Advertisement
T Cell Engager Technology Offers Durable Immune Reset
The scientific foundation of this acquisition lies in the emerging potential of BCMA-targeted T cell engagers, which represent a novel therapeutic modality in autoimmune disease treatment. By targeting B cell maturation antigen (BCMA), OM336 enables the selective depletion of disease-driving immune cells, potentially leading to a durable immune reset.
Unlike conventional immunosuppressive therapies that require continuous administration, this approach may allow patients to achieve long-lasting remission without ongoing treatment, significantly improving quality of life and reducing long-term healthcare burden.
Clinical data suggests that T cell engagers can reduce systemic inflammation, restore immune balance, and improve organ-level disease outcomes, making them a promising alternative to existing therapies. This aligns with Gilead’s broader strategy of integrating advanced immunology platforms, including CAR-T therapies and biologics, to redefine standards of care in chronic inflammatory diseases.
Collaboration with Galapagos Strengthens Development Strategy
In addition to the acquisition, Gilead is in advanced discussions with Galapagos NV to establish a strategic research and development collaboration focused on the acquired Ouro portfolio. Under the proposed agreement, Galapagos would share financial responsibilities, including 50% of upfront and milestone payments, while taking on a significant role in development activities.
The collaboration is expected to accelerate the clinical development and commercialization of OM336, leveraging Galapagos’ expertise in drug development and Gilead’s global commercialization capabilities. Gilead will retain worldwide commercialization rights, excluding Greater China, and will provide royalties to Galapagos based on net sales.
This partnership-driven model reflects a broader industry trend toward shared innovation and risk in drug development, enabling faster advancement of promising therapies while optimizing resource allocation.
Strengthening Leadership in Biopharma Innovation
The acquisition underscores Gilead’s commitment to investing in innovative science and expanding its immunology pipeline. By integrating Ouro’s T cell engager platform, Gilead is positioning itself at the forefront of next-generation autoimmune therapies, with the potential to deliver durable, disease-modifying treatments.
As the pharmaceutical industry continues to evolve toward precision medicine and advanced biologics, strategic acquisitions like this highlight the importance of pipeline diversification and early-stage innovation. With OM336 and future assets from the Ouro portfolio, Gilead aims to transform treatment paradigms for patients with chronic immune-mediated diseases, reinforcing its role as a leader in global biopharmaceutical innovation.
Source: Gilead Sciences, Ouro Medicines press release
